Two weeks ago, we reported that pembrolizumab worked well as first-line treatment for advanced lung cancer patients. Those benefits―which included a 40% reduction in risk of death compared to chemotherapy―led the FDA to grant Breakthrough Therapy Designation and Priority Review to the therapy.
Although the FDA had until December 24 to make a decision, U.S. regulators decided yesterday, two months ahead of schedule, to approve pembrolizumab (Keytruda ®, Merck) as a first-line option for patients with advanced non-small cell lung carcinoma (NSCLC). It’s important to note, however, that this approval is for patients whose tumors have high PD-L1 expression (more than half the cells expressed it) and don’t have any mutations in EGFR or ALK. Pembrolizumab is an anti-PD-1 checkpoint antibody that targets the PD-1/PD-L1 pathway and can help keep immune cells active against cancer.
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Read Previous Article
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
News and research from Drs. Claire Friedman, Ian Frazer, and Cornelis Melief on changing the future of cervical cancer treatment.
How the video game live stream fundraiser “Prepare to Destroy Cancer” is supporting cancer immunotherapy research